[Research Progress of Immune Checkpoint Inhibitors  in Malignant Pleural Mesothelioma].

Yaru Huang, Qingwei Meng

Open access · greenAbstract readReview

In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.1field-weighted citation impact, top 49% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study.Journal of thoracic disease · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Yaru HuangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150000, China.

Qingwei MengDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150000, China.

Harbin Medical University · CNThird Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is a malignant tumor with strong invasiveness, low survival rate and lack of effective treatment options. As the only first-line treatment plan for the advanced MPM, combination of pemetrexed and cisplatin chemotherapy have been existing since the last 20 years. Immunotherapy has long been considered as a potential treatment plan for MPM, mainly including immune checkpoint inhibitors (ICIs), immunotoxin therapy, anti-cancer vaccine and adoptive T-cell therapy. This review focuses on summarizing the current research status of immune checkpoint inhibitors in MPM, discusses the effect of tumor heterogeneity on ICIs treatment, and describes that the biomarker-oriented immunotherapy is a new vision for the realization of individualized treatment of MPM. .

Indexed as

Mesothelioma, MalignantPleural NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Agents, ImmunologicalBiomarkers, TumorBiomedical ResearchHumansImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Agents, ImmunologicalBiomarkers, TumorImmune Checkpoint InhibitorsBiomarkersImmune checkpoint inhibitorsImmunotherapyMalignant pleural mesotheliomaTumor heterogeneity

Identifiers

PMID34157803

DOI10.3779/j.issn.1009-3419.2021.102.18

PMCPMC8246391

OpenAlexW3175716548

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.